EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clemastine fumarate promotes myelin repair in a nonhuman primate model of demyelination characterized by absent spontaneous remyelination

Nadège Sarrazin iD, Rafik Arab iD, Christian Cordano iD, Elena Brazhnikova iD, Jérémy Chazot iD, Fabrice Arcizet iD, Corinne Bachelin iD, Dominique Langui iD, Daniel J Bennett iD, Ahmed Abdelhak, Harkeerat Halait, Pierre Moissonnier iD und 4 weitere

Proceedings of the National Academy of Sciences · 2026

DOI: 10.1073/pnas.2520161123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Nadège Sarrazin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Paris Brain Institute, CNRS, INSERM, Sorbonne Université, Paris F-75013, France. Hauptthemen laut MEDLINE: Clemastine, Remyelination, Demyelinating Diseases, Myelin Sheath. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Promotion of remyelination has become a new therapeutic avenue, to prevent neuronal degeneration and promote recovery in white matter diseases such as multiple sclerosis. Clemastine fumarate among several promyelinating agents, has been validated as a promyelinating agent in rodents and has led to a first successful double-blind, placebo-controlled clinical trial evaluating a remyelinating therapy for multiple sclerosis (MS) [A. J. Green et al. , Lancet 390 , 2481–2489 (2017)]. To date, most of promyelinating strategies have been developed in short-lived rodent models of demyelination, which spontaneously repair. Well-defined nonhuman primate models closer to man would allow to efficiently advance therapeutic approaches, and namely to assess noninvasively, their efficacy in promoting functional repair. We developed a nonhuman primate model of optic nerve demyelination which leads to failed remyelination, progressive neuronal degeneration, and visual dysfunction, thus recapitulating several features of MS lesions and providing the missing link to translate emerging preclinical therapies to the clinic for myelin disorders such as multiple sclerosis [N. Sarrazin et al. , Proc. Natl. Acad. Sci. U.S.A. 119 , e2115973119 (2022)]. We used this model to assay the therapeutic benefits of clemastine. Our histological and ultrastructural findings show that clemastine is able to overcome the failed remyelination of the nonhuman primate optic nerve. We also used visual evoked potential, optical coherence tomography, and electroretinogram as noninvasive means to follow up the optic nerve de/remyelination process and correlated these findings with postmortem analysis to establish the safety and efficacy of clemastine therapy in promoting functional and morphological recovery in nonhuman primates. We demonstrate that clemastine can overcome chronic demyelination in nonhuman primates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClemastineRemyelinationDemyelinating DiseasesMyelin SheathAnimalsDisease Models, AnimalOptic NerveMale

Stichwörter der Autor:innen

clemastine fumaratdemyelinationnonhuman primateoptic nervepromyelinating compound

Substanzen

Clemastine

Autor:innen und Institutionen

  • Paris Brain Institute, CNRS, INSERM, Sorbonne Université, Paris F-75013, France.
  • INSERM, CNRS, Institut de la Vision, Sorbonne Université, Paris F-75012, France.
  • Weill Institute for Neuroscience, University of California San Francisco, San Francisco, CA 94117.
  • Department of Small Animal Surgery, VetAgro Sup, Marcy L'Etoile F-69280, France.

ORCID-Profile: Nadège Sarrazin, Rafik Arab, Christian Cordano, Elena Brazhnikova, Jérémy Chazot, Fabrice Arcizet, Corinne Bachelin, Dominique Langui, Daniel J Bennett, Pierre Moissonnier, Céline Nouvel-Jaillard, Ari J Green, Anne Baron-Van Evercooren

Förderung

  • NINDS NIH HHS

Zitieren

APA

Sarrazin, N., Arab, R., Cordano, C., Brazhnikova, E., Chazot, J., Arcizet, F., Bachelin, C., Langui, D., Bennett, D. J., Abdelhak, A., Halait, H., Moissonnier, P., Nouvel-Jaillard, C., Pouget, P., Green, A. J., & Baron-Van Evercooren, A. (2026). Clemastine fumarate promotes myelin repair in a nonhuman primate model of demyelination characterized by absent spontaneous remyelination. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2520161123

Vancouver

Sarrazin N, Arab R, Cordano C, Brazhnikova E, Chazot J, Arcizet F, et al. Clemastine fumarate promotes myelin repair in a nonhuman primate model of demyelination characterized by absent spontaneous remyelination. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2520161123

BibTeX
@article{Sarrazin2026,
  author = {Sarrazin, Nadège and Arab, Rafik and Cordano, Christian and Brazhnikova, Elena and Chazot, Jérémy and Arcizet, Fabrice and Bachelin, Corinne and Langui, Dominique and Bennett, Daniel J and Abdelhak, Ahmed and Halait, Harkeerat and Moissonnier, Pierre and Nouvel-Jaillard, Céline and Pouget, Pierre and Green, Ari J and Baron-Van Evercooren, Anne},
  title = {Clemastine fumarate promotes myelin repair in a nonhuman primate model of demyelination characterized by absent spontaneous remyelination},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  doi = {10.1073/pnas.2520161123}
}
Kostenlos starten →